DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
The generic ingredient in NUZYRA is omadacycline tosylate. Additional details are available on the omadacycline tosylate profile page.
Generic Entry Opportunity Date for 209816
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 150MG BASE|
|Approval Date:||Oct 2, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Oct 2, 2028|
|Regulatory Exclusivity Use:||GENERATING ANTIBIOTIC INCENTIVES NOW|
|Regulatory Exclusivity Expiration:||Oct 2, 2023|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||Start Trial||Patent Expiration:||Aug 3, 2037||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION|
Complete Access Available with Subscription